Compare AbCellera Biologics Inc (ABCL) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Lowe`s Companies Inc — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Lowe`s Companies Inc trades at $214.17 (market cap $123.86B). The key difference: Lowe`s Companies Inc is far larger — about 52.7× AbCellera Biologics Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LOW | |
|---|---|---|
Market Cap | $2.35B | $123.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $287.39 |
52-Week Low | $2.78 | $206.62 |
Enterprise Value | $1.99B | $165.61B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Lowe's (LOW) trades at $220.9, down 2.9% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 60.79% buy rating from analysts support optimism, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock's P/E of 18.92 and net income margin of 7.51% reflect solid profitability, while dividend increases counter earlier Wall Street skepticism about payout sustainability.
The outlook is positive with a $260.88 consensus price target, but risks include high debt levels, competitive pressure from Home Depot, and macroeconomic sensitivity. Earnings growth and professional market expansion are key catalysts, though inflation and housing market softness pose headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
